BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:First in human evaluation of CDK9 inhibition with KB-0742 in solid
  tumors - Richard Cutler PhD\, Kronos Bio\, Inc.
DTSTART:20231106T130000Z
DTEND:20231106T140000Z
UID:TALK204280@talks.cam.ac.uk
CONTACT:Kate Davenport
DESCRIPTION:KB-0742\, is a CDK9 inhibitor\, that originated from a Kronos 
 Bio proprietary drug screen.  CDK9 is a global regulator of transcription 
 and a critical node in multiple oncogenic transcription regulated networks
 .  KB-0742 is in an ongoing Phase 1/2 study.  Details of the study will be
  presented.  
LOCATION:CRUK CI Lecture Theatre
END:VEVENT
END:VCALENDAR